WO2002005818A3 - Novel method of use of multidrug resistance modulators - Google Patents

Novel method of use of multidrug resistance modulators Download PDF

Info

Publication number
WO2002005818A3
WO2002005818A3 PCT/US2001/016516 US0116516W WO0205818A3 WO 2002005818 A3 WO2002005818 A3 WO 2002005818A3 US 0116516 W US0116516 W US 0116516W WO 0205818 A3 WO0205818 A3 WO 0205818A3
Authority
WO
WIPO (PCT)
Prior art keywords
multidrug resistance
novel method
resistance modulators
modulators
mammal
Prior art date
Application number
PCT/US2001/016516
Other languages
French (fr)
Other versions
WO2002005818A2 (en
Inventor
Anne Hollins Dantzig
Kevin Lynn Law
James Jacob Starling
Original Assignee
Lilly Co Eli
Anne Hollins Dantzig
Kevin Lynn Law
James Jacob Starling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Anne Hollins Dantzig, Kevin Lynn Law, James Jacob Starling filed Critical Lilly Co Eli
Priority to AU2001269708A priority Critical patent/AU2001269708A1/en
Publication of WO2002005818A2 publication Critical patent/WO2002005818A2/en
Publication of WO2002005818A3 publication Critical patent/WO2002005818A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of suppressing multidrug resistance in a mammal by administering an effective amount of a 10,11-methanodibenzosuberane derivative or a pharmaceutically acceptable salt thereof.
PCT/US2001/016516 2000-07-18 2001-07-05 Novel method of use of multidrug resistance modulators WO2002005818A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001269708A AU2001269708A1 (en) 2000-07-18 2001-07-05 Novel method of use of multidrug resistance modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21922200P 2000-07-18 2000-07-18
US60/219,222 2000-07-18

Publications (2)

Publication Number Publication Date
WO2002005818A2 WO2002005818A2 (en) 2002-01-24
WO2002005818A3 true WO2002005818A3 (en) 2003-01-16

Family

ID=22818379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016516 WO2002005818A2 (en) 2000-07-18 2001-07-05 Novel method of use of multidrug resistance modulators

Country Status (2)

Country Link
AU (1) AU2001269708A1 (en)
WO (1) WO2002005818A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008490A2 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024107A1 (en) * 1993-04-19 1994-10-27 Syntex (U.S.A.) Inc. 10,11-methanodibenzosuberane derivatives used as chemosensitizing agents
WO1997048689A1 (en) * 1996-06-17 1997-12-24 Eli Lilly And Company Drug resistance and multidrug resistance modulators
WO1998022112A1 (en) * 1996-11-22 1998-05-28 Eli Lilly And Company Drug resistance and multidrug resistance modulators
WO1999017757A1 (en) * 1997-10-08 1999-04-15 Dzieglewska Hanna Eva USE OF P-GLYCOPROTEIN (Pgp) INHIBITORS IN THE TREATMENT OF CANCER
WO2000075121A2 (en) * 1999-06-03 2000-12-14 Eli Lilly And Company Process for preparing 10,11-methanobenzosuberane derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024107A1 (en) * 1993-04-19 1994-10-27 Syntex (U.S.A.) Inc. 10,11-methanodibenzosuberane derivatives used as chemosensitizing agents
WO1997048689A1 (en) * 1996-06-17 1997-12-24 Eli Lilly And Company Drug resistance and multidrug resistance modulators
WO1998022112A1 (en) * 1996-11-22 1998-05-28 Eli Lilly And Company Drug resistance and multidrug resistance modulators
WO1999017757A1 (en) * 1997-10-08 1999-04-15 Dzieglewska Hanna Eva USE OF P-GLYCOPROTEIN (Pgp) INHIBITORS IN THE TREATMENT OF CANCER
WO2000075121A2 (en) * 1999-06-03 2000-12-14 Eli Lilly And Company Process for preparing 10,11-methanobenzosuberane derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 131, no. 19, 8 November 1999, Columbus, Ohio, US; abstract no. 252206b, DANTZIG,AQ.H. ET AL.: "Selectivity of the multidrug resistance modulator LY335979, for P-glycoprotein and effect on cytochrome P-450 activities." page 36; XP002204882 *
G.L.LUKER ET AL.: "Effects if Cholesterol and Enantiomeric Cholesterol on P-Glycoprotein Localization and Function in Low-Density Membrane Domains", BIOCHEMISTRY, vol. 39, 7 June 2000 (2000-06-07), pages 7651 - 7661, XP002204874 *
G.L.LUKER ET AL.: "Multidrug Resistance (MDR1) P-glycoprotein Enhances Esterification of Plasma Membrane Cholesterol", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 11, 1999, USA, pages 6979 - 6991, XP002204873 *
J. PHARMACOL. EXP. THER., vol. 290, no. 2, 1999, pages 854 - 862 *

Also Published As

Publication number Publication date
WO2002005818A2 (en) 2002-01-24
AU2001269708A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
AU2001282735A1 (en) Event-based advertisements
AU2001269799A1 (en) Methods for treating various eye disorders
AU2001278385A1 (en) Unipolar transverse flux machine
AU2002359923A1 (en) 6-fluorobicyclo[3.1.0]hexane derivatives
AU2001285446A1 (en) Called party billing
AU2001219185A1 (en) 2-acylaminobenzimidazole derivatives for treating glaucoma
AU2001279664A1 (en) Endoparasiticidal agents for voluntary oral ingestion by animals
AU2001240026A1 (en) Camptothecin conjugates
AU2001251087A1 (en) Tubular intravenous set
AU2002210881A1 (en) Transdermal method
AU2002356533A1 (en) Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
AU2001237939A1 (en) Methods for treating glaucoma
AU5495101A (en) Ophthalmic injector
AU4315700A (en) N-substituted dihydropyrrole derivatives
AU2002241670A1 (en) Method for treating glaucoma IB
AU2002236455A1 (en) Synergistic ecta compositions
AU2001270883A1 (en) Tubing injector
AU4009497A (en) Substituted pyrazolyl-pyrazole derivatives, process for their preparation nd their use as agents with a herbicidal effect
AU2002214657A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
WO2002005818A3 (en) Novel method of use of multidrug resistance modulators
AU2001229642A1 (en) Impact modified polyamide composition
AU2002223655A1 (en) Indolylpiperidine derivatives as antihistaminic and antiallergic agents
AU2001268653A1 (en) Combination hiv therapy including camptothecin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP